Update shared on27 Sep 2025
Fair value Increased 59%Upward revisions to 4DMedical’s revenue growth forecasts have driven a higher future P/E multiple, resulting in a substantial increase in the consensus analyst price target from A$0.90 to A$1.43.
What's in the News
- 4DMedical announced FDA 510(k) clearance and CMS reimbursement confirmation for CT:VQ, its non-contrast, ventilation-perfusion imaging software delivered as SaaS, enabling functional lung imaging on standard CT scanners without new hardware.
- CT:VQ integrates into existing radiology workflows, broadening access to reimbursable V/Q studies for hospitals and centers lacking nuclear medicine, particularly benefitting community and rural patients.
- Clinical validation included performance testing against SPECT scans, reader studies, and multi-condition real-world cases; early adopters include Stanford University and Brooke Army Medical Center.
- 4DMedical was dropped from the S&P/ASX All Ordinaries Index.
Valuation Changes
Summary of Valuation Changes for 4DMedical
- The Consensus Analyst Price Target has significantly risen from A$0.90 to A$1.43.
- The Future P/E for 4DMedical has significantly risen from 64.20x to 102.35x.
- The Consensus Revenue Growth forecasts for 4DMedical has significantly risen from 89.8% per annum to 113.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.